bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S3 from Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
Authors: Wang Jian , Yang Shouhui , He Peijun , Schetter Aaron J. , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Gaida Matthias M. , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Table S3: List of 1820 differentially expressed genes between short and long survival groups
Figure S4 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Figure S4 Figure S4. Association between variables reflecting chromosomal instability variables and tumor mutational burden (TMB) per Mb. (A-C) Scatterplots are displayed to represent the association between two quantitative variables (TMB per Mb and number of large deletions and losses of heterozygosity (LOH)). (D-I) Association between one quantitative variable and one qualitative variable (ploidy state and categorized copy number alteration (CNA) clones) are shown through boxplots, and (J) cumulative barplots are used to represent association between the two qualitative variables. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001; ns: not significant.
Supplementary Figure S1, S2, S3 from Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer
Authors: Wang Jian , Yang Shouhui , He Peijun , Schetter Aaron J. , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Gaida Matthias M. , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Figure S1: Representative pictures of immunohistochemical staining, showing NOSTRIN expression largely in the tumor cells in the patient with long survival. Figure S2: NOSTRIN overexpression sensitizes the Panc1 pancreatic cancer cells to gemcitabine. Figure S3: (a) A negative correlation existed between miR-222 and NOSTRIN expression in tumors from PDAC cases (N=37). (b) miR-222 expression does not show any significant association with survival. (ns=non significant).
Figure S3 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Figure S3 Figure S3. (A) Kaplan-Meier estimates for overall survival (OS); patients were stratified according to their tumor mutational burden (TMB) per Mb: low rate (in red) or high rate (in blue). (B-H) KaplanMeier estimates for OS; patients were stratified according to their proportion of signatures 1A (B), 1B (C), 3 (D), 4 (E), 6 (F), 16 (G), and 21 (H): low proportion (in red) or high proportion (in blue). The cutoffs were those defined for progression-free survival with the Cutoff Finder method. *: p < 0.05; **: p < 0.01; ***: p < 0. 001; ****: p < 0.0001; ns: not significant.
Table S1 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Clinicopathological characteristics of cervical cancer and endometrial cancer patients.
Supplementary information from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Supplementary info
Table S4 from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Shows the maximum standard uptake values (SUVmax) for primary and metastatic lesions observed in the three subjects, decay corrected to the time of injection.
Figure S4 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Changes in the livers of mice that were subcutaneously inoculated with G-CSF-producing cervical cancer.
Table S2 from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Shows the biodistribution data for [18F]αvβ6-BP in mice bearing paired αvβ6-expressing DX3puroβ6 and non-αvβ6-expressing DX3puro xenograft tumors at 1, 2 and 4 h p.i. and at 1 h p.i. after pre-administration of blocking peptide. Tissue uptake is expressed as decay-corrected percent injected dose per gram of tissue (dc % ID/g)
Figure S3 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Metastatic ability of the subcutaneous tumor model.
Figure S1 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

. The serum G-CSF concentrations of newly diagnosed endometrial cancer patients according to their neutrophil counts.
Figure S2 from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Shows the in vivo stability of [18F]αvβ6-BP in human blood. Representative radio-HPLC of blood sample taken 30 min post injection. Top: Sample only; bottom: sample spiked with [18F]αvβ6-BP. X-axis: retention time [min]; Y-axis: detector response [volts].
Figure S5 from Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Authors: Weberpals Johanne I. , Lo Bryan , Duciaume Marc M. , Spaans Johanna N. , Clancy Aisling A. , Dimitroulakos Jim , Goss Glenwood D. , Sekhon Harman S.
Published: April 2023

Kapplan-Meir curves of Overall Survival (OS)
Supplementary Figure Legends from Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Authors: Engstrom Lars D. , Aranda Ruth , Lee Matthew , Tovar Elizabeth A. , Essenburg Curt J. , Madaj Zachary , Chiang Harrah , Briere David , Hallin Jill , Lopez-Casas Pedro P. , Baños Natalia , Menendez Camino , Hidalgo Manuel , Tassell Vanessa , Chao Richard , Chudova Darya I. , Lanman Richard B. , Olson Peter , Bazhenova Lyudmilla , Patel Sandip Pravin , Graveel Carrie , Nishino Mizuki , Shapiro Geoffrey I. , Peled Nir , Awad Mark M. , Jänne Pasi A. , Christensen James G.
Published: April 2023

Supplementary Figure Legends
Figure S4 from Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Authors: Weberpals Johanne I. , Lo Bryan , Duciaume Marc M. , Spaans Johanna N. , Clancy Aisling A. , Dimitroulakos Jim , Goss Glenwood D. , Sekhon Harman S.
Published: April 2023

Kapplan-Meir curve of Time to Progression
Supplemental video S4 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Authors: Kreutzman Anna , Colom-Fernández Beatriz , Jiménez Ana Marcos , Ilander Mette , Cuesta-Mateos Carlos , Pérez-García Yaiza , Arévalo Cristina Delgado , Brück Oscar , Hakanen Henna , Saarela Jani , Ortega-Carrión Alvaro , de Rosendo Ana , Juanes-García Alba , Steegmann Juan Luis , Mustjoki Satu , Vicente-Manzanares Miguel , Muñoz-Calleja Cecilia
Published: April 2023

Wound healing in the presence of 100 nM dasatinib.
Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Authors: Somlo George , Frankel Paul H. , Arun Banu K. , Ma Cynthia X. , Garcia Agustin A. , Cigler Tessa , Cream Leah V. , Harvey Harold A. , Sparano Joseph A. , Nanda Rita , Chew Helen K. , Moynihan Timothy J. , Vahdat Linda T. , Goetz Matthew P. , Beumer Jan H. , Hurria Arti , Mortimer Joanne , Piekarz Richard , Sand Sharon , Herzog Josef , Van Tongeren Lily R. , Ferry-Galow Katherine V. , Chen Alice P. , Ruel Christopher , Newman Edward M. , Gandara David R. , Weitzel Jeffrey N.
Published: April 2023

Veliparib pharmacokinetics with geometric mean* and standard deviation (SD) plasma pharmacokinetic parameters during the phase I combination phase
Figure S5 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Authors: Kreutzman Anna , Colom-Fernández Beatriz , Jiménez Ana Marcos , Ilander Mette , Cuesta-Mateos Carlos , Pérez-García Yaiza , Arévalo Cristina Delgado , Brück Oscar , Hakanen Henna , Saarela Jani , Ortega-Carrión Alvaro , de Rosendo Ana , Juanes-García Alba , Steegmann Juan Luis , Mustjoki Satu , Vicente-Manzanares Miguel , Muñoz-Calleja Cecilia
Published: April 2023

Evans Blue endothelial permeability assay shows leakage in the intestine of mice treated with dasatinib.
Supplementary Tables from Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer
Authors: Rosati Rayna , Polin Lisa , Ducker Charles , Li Jing , Bao Xun , Selvakumar Dakshnamurthy , Kim Seongho , Xhabija Besa , Larsen Martha , McFall Thomas , Huang Yanfang , Kidder Benjamin L. , Fribley Andrew , Saxton Janice , Kakuta Hiroki , Shaw Peter , Ratnam Manohar
Published: April 2023

Supplementary Tables #1-4
Supplementary table 9 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Supplementary Methods from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Authors: Zuo Wen-Jia , Jiang Yi-Zhou , Wang Yu-Jie , Xu Xiao-En , Hu Xin , Liu Guang-Yu , Wu Jiong , Di Gen-Hong , Yu Ke-Da , Shao Zhi-Ming
Published: April 2023

Supplementary Methods: Immunofluorescence
Supplementary Data - Figure 4 from SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer
Authors: Tao Zhen , McCall Neal S. , Wiedemann Norbert , Vuagniaux Grégoire , Yuan Zhiyong , Lu Bo
Published: April 2023

CD8+ T cells are required for the efficacy of Debio 1143/ART combination therapy in an LLC mouse model without OVA expression. The CD8 depletion experiment (Figure 4A) was repeated using LLC cells, rather than LLC-OVA cells (n=12 mice per group). LLC tumors were again allowed to grow in mice. On Day 9, mice were treated with anti-CD8 antibody, IgG (vehicle control), ART (30Gy), Debio 1143, or a combination of the three as shown (n=12 per group). Statistical differences were assessed using the unpaired student t-test. P-values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001.
Supplementary table 4 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Supplementary table 3 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Supplemental Table 1 from CD103 and Intratumoral Immune Response in Breast Cancer
Authors: Wang Zhi-Qiang , Milne Katy , Derocher Heather , Webb John R. , Nelson Brad H. , Watson Peter H.
Published: April 2023

Supplemental Table 1. A report concerning the source of the biospecimen and data using the BRISQ guidelines.
Figure S1 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary Figure
Supplemental Figure 1 from CD103 and Intratumoral Immune Response in Breast Cancer
Authors: Wang Zhi-Qiang , Milne Katy , Derocher Heather , Webb John R. , Nelson Brad H. , Watson Peter H.
Published: April 2023

Supplemental Figure 1: Prognostic impact of CD103 and CD8 in the Basel-like subset of breast cancers.
Online supplement from Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer
Authors: Kurland Brenda F. , Peterson Lanell M. , Lee Jean H. , Schubert Erin K. , Currin Erin R. , Link Jeanne M. , Krohn Kenneth A. , Mankoff David A. , Linden Hannah M.
Published: April 2023

Supplementary results Table S1. Agreement of predefined classifiers (n=90). Figure S1. Scatterplot of imaging parameter agreement. Figure S2. Association of clinical benefit (progression-free survival > 6 months on endocrine therapy) with quantitative imaging biomarkers predicting endocrine response, defined in Table 1. A. FES dynSUV B. FES SULmean3 C. FES/FDG ratio3. â-¬ is median, â-Š is mean. None are associated with PFS6 by logistic regression (N=76, Wald test p>0.10). Figure S3. Results of analysis using recursive partitioning to predict PFS by selected imaging parameters (FES SUVmax3, FES SULmax3, and FDG SUVmax3) Figure S4. Association of log(FDG SULmax) with reconstruction of the same scan by filtered back-projection (X axis) or ordered-subset expectation maximization (Y axis). Figure S5. Association FES SULmean with reconstruction of the same scan by filtered backprojection (X axis) or ordered-subset expectation maximization (Y axis) for 93 lesions in 16 patients from this study.
Supplementary Video S3 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Live cell imaging of histone-H2B-RFP expressing PCI13-G245D cells treated with vorinostat and AZD1775 combination.
Supplementary Figures from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types
Authors: Chüeh Anderly C. , Tse Janson W.T. , Dickinson Michael , Ioannidis Paul , Jenkins Laura , Togel Lars , Tan BeeShin , Luk Ian , Davalos-Salas Mercedes , Nightingale Rebecca , Thompson Matthew R. , Williams Bryan R.G. , Lessene Guillaume , Lee Erinna F. , Fairlie Walter D. , Dhillon Amardeep S. , Mariadason John M.
Published: April 2023

Supplementary Figures
Supplementary Video S2 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Live cell imaging of histone-H2B-RFP expressing PCI13-G245D cells in the presence of vorinostat.
Figure S6 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Fig. S6. Treatment arms stratified by colon cancer subtype in the CAIRO cohort
Supplementary Figures and Tables from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer
Authors: Liu Hong , Xu Yiyang , Xiang Jingyi , Long Li , Green Shon , Yang Zhiyuan , Zimdahl Bryan , Lu Jingwei , Cheng Neal , Horan Lucas H. , Liu Bin , Yan Su , Wang Pei , Diaz Juan , Jin Lu , Nakano Yoko , Morales Javier F. , Zhang Pengbo , Liu Lian-xing , Staley Binnaz K. , Priceman Saul J. , Brown Christine E. , Forman Stephen J. , Chan Vivien W. , Liu Cheng
Published: April 2023

Supplementary Figure S1. Epitope mapping of clones A-D by alanine scanning mutagenesis. Supplementary Figure S2. Analysis of the selectivity of ET1402L1 (clone B) towards AFP158. Supplementary Figure S3. Analysis of the potential risk for cross-presentation of AFP158 by normal cells. Supplementary Figure S4. Co-incubation of AFP-CAR T cells with antigen-positive cells induces production and release of cytokines. Supplementary Figure S5. AFP-CAR T cells can penetrate laminin-rich Matrigel and specifically kill AFP+/A2+ cells in vitro. Supplementary Figure S6. Representative quality control tests performed on each batch of AFP-CAR T cells manufactured for in vivo studies. Supplementary Figure S7. T cell subset analysis to determine distribution of TNaive, TCM TEM, and TEffector cell populations. Supplementary Figure S8. Analysis of human CD3+ T cells in Hep G2 s.c. tumors from i.v.- treated mice. Supplementary Figure S9. Determination of the number of AFP158/HLA-A*02:01 complexes expressed on the surface of liver cancer cells. Supplementary Table S1. Chimeric mouse IgG1 antibody binding affinity to AFP158/HLAA* 02:01.
Figure S2 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Fig. S2. Overview of CMS classification scheme
Figure S1 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Authors: Trinh Anne , Trumpi Kari , De Sousa E Melo Felipe , Wang Xin , de Jong Joan H. , Fessler Evelyn , Kuppen Peter J.K. , Reimers Marlies S. , Swets Marloes , Koopman Miriam , Nagtegaal Iris D. , Jansen Marnix , Hooijer Gerrit K.J. , Offerhaus George J.A. , Kranenburg Onno , Punt Cornelis J. , Medema Jan Paul , Markowetz Florian , Vermeulen Louis
Published: April 2023

Fig. S1. Patient selection and omission
Supplementary Tables S1-S12 from Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Authors: Landa Iñigo , Pozdeyev Nikita , Korch Christopher , Marlow Laura A. , Smallridge Robert C. , Copland John A. , Henderson Ying C. , Lai Stephen Y. , Clayman Gary L. , Onoda Naoyoshi , Tan Aik Choon , Garcia-Rendueles Maria E.R. , Knauf Jeffrey A. , Haugen Bryan R. , Fagin James A. , Schweppe Rebecca E.
Published: April 2023

Supplementary Table S1. Cell line authentication by Short Tandem Repeat Profiling (STR) Supplementary Table S2. Full list of genetic variants identified by MSK-IMPACT sequencing Supplementary Table S3. Details for identified high-confidence gene rearrangements resulting in in-frame fusion proteins Supplementary Table S4. Recurrent copy number alterations in thyroid cancer cell lines. Supplementary Table S5. Genes located within the recurrent copy number alteration regions. Supplementary Table S6. Differentially expressed genes, which are located within CNA regions. "Matching_CNA_type" column indicates whether the direction of the expression change corresponds to the CNA type (133 out of 134, overexpression for gene amplification and underexpression for gene deletions). Supplementary Table S7. Thyroid cancer cell lines gene expression data. Normalized gene expression values for all genes in the 44 cell lines assessed by Affymetrix expression microarray in this study ("CU" prefix, University of Colorado). Supplementary Table S8. Genes with differential expression in PTC vs. ATC cell lines. List of differentially expressed genes between PTC-derived vs. ATC-derived cell lines (limma, adjusted p-value<0.05). Supplementary Table S9. Genes with differential expression in PTC vs. ATC tumors. List of top 1000 differentially expressed genes when comparing PTC vs. ATC tumors from other studies (19,20), assessed with the same platform used for cell line transcriptomic profiling. Supplementary Table S10. Thyroid differentiation score (TDS) in thyroid cancer cell lines and tissues. TDS values are calculated for 44 cell lines from this study ("CU" prefix, University of Colorado) and thyroid tissues from other studies, assessed with the same platform: 9 PTC-normal pairs ("He", (19)) 17 PDTCs and 20 ATCs ("Landa", (20)). Supplementary Table S11. Association of TDS16 and TDS13 with clinical and histopathologic characteristics of PTC tumors from the TCGA. P-values calculated with Kruskal-Wallis rank sum test are shown. Supplementary Table S12. BRAFV600E-RAS scores (BRS) and the sensitivity of thyroid cancer cell lines to trametinib and PD-0325901. Drug sensitivity is expressed as a relative area under the dose response curve.
Supplemental Figure 4 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

Supplemental Figure 4 Phenotypic analysis of initial and final patient products.
Figure S1 from Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer
Authors: van der Wekken A.J. , Pelgrim R. , 't Hart N. , Werner N. , Mastik M.F. , Hendriks L. , van der Heijden E.H.F.M. , Looijen-Salamon M. , de Langen A.J. , Staal-van den Brekel J. , Riemersma S. , van den Borne B.E. , Speel E.J.M. , Dingemans A-M.C. , Hiltermann T.J.N. , van den Berg A. , Timens W. , Schuuring E. , Groen H.J.M.
Published: April 2023

Flow diagram of patients in study cohort and external validation
Supplemental Figure 4 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Authors: Dovedi Simon J. , Cheadle Eleanor J. , Popple Amy L. , Poon Edmund , Morrow Michelle , Stewart Ross , Yusko Erik C. , Sanders Catherine M. , Vignali Marissa , Emerson Ryan O. , Robins Harlan S. , Wilkinson Robert W. , Honeychurch Jamie , Illidge Timothy M.
Published: April 2023

Concurrent but not sequential blockade of PD-1 is required to augment the efficacy of fractionated RT
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

The ctDNA panel (Guardant360{trade mark, serif}) utilized here employs digital sequencing to detect mutations in 73 genes. Whole gene sequencing is performed in 19 cancer genes, critical exons coverage in 54 genes and amplifications (18 genes), fusions (6 genes) and indels (23 genes).
Supplemental Figure 3 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Authors: Dovedi Simon J. , Cheadle Eleanor J. , Popple Amy L. , Poon Edmund , Morrow Michelle , Stewart Ross , Yusko Erik C. , Sanders Catherine M. , Vignali Marissa , Emerson Ryan O. , Robins Harlan S. , Wilkinson Robert W. , Honeychurch Jamie , Illidge Timothy M.
Published: April 2023

The relative frequency of the top 25 clones from tumor 1 tracked in pre-therapy blood, post-therapy blood, and in tumor 2 post-therapy
Supplementary Table S3 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
Authors: Tokunaga Ryuma , Xiu Joanne , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Naseem Madiha , Lo Jae Ho , Arai Hiroyuki , Battaglin Francesca , Puccini Alberto , Berger Martin D. , Soni Shivani , Zhang Wu , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Baba Hideo , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Supplementary Table S3. Associations of molecular characteristics with the location of tumor sampling
Supplementary Figure 7 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Fluctuating volume percentages detected for HNSCC metastatic lymph node ROIs between two MR sessions 48 hours apart (solid lines - responders, dashed lines - non responders).
Supplementary Figure 6 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Examples of Ktrans and R2* distributions for fluctuating and non-fluctuating parts of human HNSCC (Patient No 5, N2). The non-enhancing part of the tumor (Ktrans = 0) is indicated with an asterisk.
Supplementary Figure 4 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

T2*-weighted image (TE=4.9 ms) for a stage IV HNSCC patient (Pt No: 5). Marker lines represent image positions used in the assessment of motion correction. B: Time traces of nodal (LN) and primary (P) projections without (S(t)) and with motion correction (S(t)MOCO). Pronounced global motion (i.e. swallowing) is marked with an asterisk. Persistent motion artifacts present in the primary tumor are indicated with an arrow.
Figure S5 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Wildes Tyler J. , Grippin Adam , Dyson Kyle A. , Wummer Brandon M. , Damiani David J. , Abraham Rebecca S. , Flores Catherine T. , Mitchell Duane A.
Published: April 2023

T cell-released soluble factors induce HSPC differentiation only after recognition of antigen-matched target cells.
Suppl Text and Figures from Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Authors: Wick Wolfgang , Gorlia Thierry , Bady Pierre , Platten Michael , van den Bent Martin J. , Taphoorn Martin J.B. , Steuve Jonathan , Brandes Alba A. , Hamou Marie-France , Wick Antje , Kosch Markus , Weller Michael , Stupp Roger , Roth Patrick , Golfinopoulos Vassilis , Frenel Jean-Sebastien , Campone Mario , Ricard Damien , Marosi Christine , Villa Salvador , Weyerbrock Astrid , Hopkins Kirsten , Homicsko Krisztian , Lhermitte Benoit , Pesce Gianfranco , Hegi Monika E.
Published: April 2023

Suppl. Materials and Methods; 5 Suppl. Figures; 2 Suppl Tables and List of Participating Investigators Supplementary Figure S1. Definition of MGMT cut-off with a safety margin. Supplementary Figure S2. Comparison of Overall Survival in patients with vs without markers assessments. Supplementary Figure S3. Visualization of markers analyzed in the mTOR signaling pathway from KEGG. Supplementary Figure S4. Forest plot molecular markers Supplementary Figure S5. Complete Graphical summary of consensus cluster analysis based on the matrix obtained by the reconstitution of the data in using Non-linear Iterative Partial Least Squares (NIPALS) algorithm.
Supplemental Table II from Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Authors: Zhu Xuguang , Enomoto Keisuke , Zhao Li , Zhu Yuelin J. , Willingham Mark C. , Meltzer Paul , Qi Jun , Cheng Sheue-yann
Published: April 2023

Gene sets enriched among genes down-regulated by JQ1
Supplementary Table 3 from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Authors: Girard Luc , Rodriguez-Canales Jaime , Behrens Carmen , Thompson Debrah M. , Botros Ihab W. , Tang Hao , Xie Yang , Rekhtman Natasha , Travis William D. , Wistuba Ignacio I. , Minna John D. , Gazdar Adi F.
Published: April 2023

Validation of the Classifier in FFPE samples
Supplemental Figure S6 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer
Authors: Mustafi Reba , Dougherty Urszula , Mustafi Devkumar , Ayaloglu-Butun Fatma , Fletcher Michelle , Adhikari Sarbani , Sadiq Farhana , Meckel Katherine , Haider Haider I. , Khalil Abdurahman , Pekow Joel , Konda Vani , Joseph Loren , Hart John , Fichera Alessandro , Li Yan Chun , Bissonnette Marc
Published: April 2023

Left panel: Western diet; Right panel: Western diet + INCB3619. Note the Alcian blue stained goblet cells appeared more abundant in INCB3619 treated mice.
Figure S4 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 4 | Whole genome CNA heatmap. (A) Genome-wide CNA heatmap profiles of all 108 OCCC tumors (above), 63 ARID1A wildtype tumors (middle) and 45 ARID1A mutant tumors (below). (B) Significant CNA plot of only ARID1A wildtype tumors (n=63) and (C) only ARID1A mutant tumors (n=45) as determined by GISTIC analysis. All kinases and cancer-related genes from the kinome sequencing gene panel that were focally significantly amplified (red) or deleted (blue) are indicated along the chromosomes vertically. Chromosomal location and total amount of tumors harboring the event are annotated with each gene name. False-discovery rate (FDR) 0.05 threshold, indicated by the green line, and G-score are shown along the horizontal axis.
Figure S2 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 2 | Significantly mutated genes AKT1, PIK3R1, ERBB3, FBXW7, ATM, CHEK2 and MYO3A. Schematics of the identified novel significantly mutated genes (A) AKT1, (B) PIK3R1, (C) ERBB3, (D) FBXW7, (E) ATM, (F) CHEK2 and (G) MYO3A in OCCC. Mutation marks are shown in black (truncating), red (SIFT and PolyPhen damaging prediction), yellow (SIFT or PolyPhen damaging prediction) or white (SIFT and PolyPhen benign prediction). Mutation effects are indicated with a black spot when paired control was available and written in black (previously described mutation) or red (novel mutations).
Supplementary material from Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Authors: Lheureux Stephanie , Lai Zhongwu , Dougherty Brian A. , Runswick Sarah , Hodgson Darren R. , Timms Kirsten M. , Lanchbury Jerry S. , Kaye Stan , Gourley Charlie , Bowtell David , Kohn Elise C. , Scott Claire , Matulonis Ursula , Panzarella Tony , Karakasis Katherine , Burnier Julia V. , Gilks C. Blake , O'Connor Mark J. , Robertson Jane D. , Ledermann Jonathan , Barrett J. Carl , Ho Tony W. , Oza Amit M.
Published: April 2023

Supplementary Figure 1. Mutational analysis of TP53 in the olaparib arm. (A) Analysis of TP53 mutation type. (B) BRCA1 and BRCA2 mutation type Supplementary Table 1. Platinum sensitivity and outcome on olaparib maintenance treatment. Supplementary Table 2. Mutational analysis of the FoundationOne® panel from the LT and ST responders in the olaparib arm. Supplementary Table 3. Mutational analysis of PTEN in the olaparib and placebo arms. Supplementary Table 4. Analysis of BRCA1, BRCA2, and TP53 mutation frequency in olaparib patients in the LT and ST responder group.
Supplementary legend from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary legend
Supplementary Fig 9 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 9
Supplementary Table S4 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Table S4. List of proteins showing statistical differences between patients diagnosed with endometrial hyperplasia (n=9) and the other non-EC controls (n=38) with adjusted p-value <0.05 and fold change > 2.
Supplementary Fig 6 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 6
Supplementary Figure S1 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Figure 1. LC-PRM data quality control. A. Coefficient of variation (CV) of the peptide signals quantified in the 116 uterine aspirates processed and analyzed by LC-PRM in duplicates. B. Plot representing the Pearson correlation coefficients between the peptides coming from the same protein.
Supplementary Fig 4 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 4
Supplementary Fig 2 from WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Authors: Luke Jason J. , Bao Riyue , Sweis Randy F. , Spranger Stefani , Gajewski Thomas F.
Published: April 2023

Sup Fig 2
Supplementary Table S3 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Kinase selectivity of 2OH-BNP1 in comparison to BAY 1816032
Supplementary Figure Legends and Methods from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Supplementary Figure Legends, Methods and References
Figure S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Cellular assays
Supplementary Figure 3 from Radiotherapy for Non–Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues
Authors: Siva Shankar , Lobachevsky Pavel , MacManus Michael P. , Kron Tomas , Möller Andreas , Lobb Richard J. , Ventura Jessica , Best Nickala , Smith Jai , Ball David , Martin Olga A.
Published: April 2023

Changes in exosome concentration in individual patients (particles per mL) over course of treatment.
SF1-4 from Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin
Authors: Rajeshkumar N.V. , Yabuuchi Shinichi , Pai Shweta G. , De Oliveira Elizabeth , Kamphorst Jurre J. , Rabinowitz Joshua D. , Tejero Héctor , Al-Shahrour Fátima , Hidalgo Manuel , Maitra Anirban , Dang Chi V.
Published: April 2023

SF 1. Heat map showing the tumor growth inhibition (TGI) of six metabolic inhibitors in PDX panel. SF 2. Tumor growth curves of PDXs treated with phenformin. SF 3. Tumor doubling time of 12 individual PDXs. SF 4. Aggregate tumor doubling time of PDXs treated with vehicle or phenformin.
figure s1 from BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models
Authors: Ganaie Arsheed A. , Beigh Firdous H. , Astone Matteo , Ferrari Marina G. , Maqbool Raihana , Umbreen Syed , Parray Aijaz S. , Siddique Hifzur R. , Hussain Tabish , Murugan Paari , Morrissey Colm , Koochekpour Shahriar , Deng Yibin , Konety Badrinath R. , Hoeppner Luke H. , Saleem Mohammad
Published: April 2023

Supplementary Figure 1. (A) Box plots show correlation of BMI1 with metastasis of CaP in a large cohort of patients as analyzed by mining of oncomine data. (B) Dot plot shows the mRNA expression of BMI1 in Caucasian vs. African American patients as analyzed by mining of GEO data from NCBI. (C) Quantitative estimation of BMI1 inhibitor and Docetaxel combination induced apoptosis in African American and Caucasian CaP models as assessed by flow cytometry. Cells were treated with BMI1 inhibitor (1.0 ï�­M) and docetaxel (10 .0 ï�­M) or combination therapy labeled with Annexin-V and PI. Live cells were gated in the forward scatter (FSC)/side scatter (SSC) plot to exclude small debris. Cells staining positive for Annexin V-FITC and negative for PI were considered to have undergone apoptosis. The images shown here are representative of three independent experiments with similar results.
Supplementary Figure S2 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Authors: Weigelt Britta , Comino-Méndez Iñaki , de Bruijn Ino , Tian Lei , Meisel Jane L. , García-Murillas Isaac , Fribbens Charlotte , Cutts Ros , Martelotto Luciano G. , Ng Charlotte K.Y. , Lim Raymond S. , Selenica Pier , Piscuoglio Salvatore , Aghajanian Carol , Norton Larry , Murali Rajmohan , Hyman David M. , Borsu Laetitia , Arcila Maria E. , Konner Jason , Reis-Filho Jorge S. , Greenberg Roger A. , Robson Mark E. , Turner Nicholas C.
Published: April 2023

Putative BRCA1 somatic reversion mutations identified in plasma DNA derived from ovarian cancer patients with BRCA1 germline mutations resistant/ refractory to platinum-based chemotherapy.
Supplementary Figure Legends from Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Authors: Orillion Ashley , Damayanti Nur P. , Shen Li , Adelaiye-Ogala Remi , Affronti Hayley , Elbanna May , Chintala Sreenivasulu , Ciesielski Michael , Fontana Luigi , Kao Chinghai , Elzey Bennett D. , Ratliff Timothy L. , Nelson David E. , Smiraglia Dominic , Abrams Scott I. , Pili Roberto
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 3 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Authors: Offin Michael , Rizvi Hira , Tenet Megan , Ni Andy , Sanchez-Vega Francisco , Li Bob T. , Drilon Alexander , Kris Mark G. , Rudin Charles M. , Schultz Nikolaus , Arcila Maria E. , Ladanyi Marc , Riely Gregory J. , Yu Helena , Hellmann Matthew D.
Published: April 2023

pre-EGFR-TKI TMB by TP53 co-mutation and incidence of TP53 co-mutation by tertile (low/intermediate vs high)
Supplementary Figure 5 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Authors: Moreno Laura , Perez Cristina , Zabaleta Aintzane , Manrique Irene , Alignani Diego , Ajona Daniel , Blanco Laura , Lasa Marta , Maiso Patricia , Rodriguez Idoia , Garate Sonia , Jelinek Tomas , Segura Victor , Moreno Cristina , Merino Juana , Rodriguez-Otero Paula , Panizo Carlos , Prosper Felipe , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure 5
Supplementary Figure 2 from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary Figure 2. Tumor mutations assayed by the Sequenom OncoCarta Panel 1.0.
Supplementary Figure 1d from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Authors: Zhu Andrew X. , Kang Yoon-Koo , Rosmorduc Olivier , Evans T.R. Jeffry , Santoro Armando , Ross Paul , Gane Edward , Vogel Arndt , Jeffers Michael , Meinhardt Gerold , Peña Carol E.A.
Published: April 2023

Supplementary Figure 1. Kaplan-Meier survival curves of treatment effect on TTP in patients with low (left panel) and high (right panel) baseline levels of (A) epiregulin (max chi interaction P value = 0.193), (B) VEGF-A (max chi interaction P value = 0.153), (C) HGF (max chi interaction P value = 0.157), and (D) PDGF (max chi interaction P value = 0.167). All biomarkers were dichotomized using the max chi optimized cutoff. BL=baseline; Erlot=erlotinib; HGF=hepatocyte growth factor; PDGF=platelet-derived growth factor; Pla=placebo; Sor=sorafenib; TTP=time to progression; VEGF=vascular endothelial growth factor.